Wells Fargo’s Benitec Biopharma BNTC Stock Holding History

Wells Fargo’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$75K	Sell	7,045 -9,217	-57%	-$107K	﹤0.01%	5262
2025 Q4	$219K	Buy	16,262 +7,129	+78%	+$98.6K	﹤0.01%	5026
2025 Q3	$128K	Buy	9,133 +1,655	+22%	+$21.1K	﹤0.01%	5186
2025 Q2	$87.5K	Buy	+7,478	New	+$105K	﹤0.01%	5277
2024 Q2	–	Sell	-17	Closed	-$89	–	6943
2024 Q1	$89	Hold	17	–	–	﹤0.01%	6689
2023 Q4	$55	Buy	17 +4	+31%	+$13	﹤0.01%	6913
2023 Q3	$39	Buy	13 +1	+8%	+$3	﹤0.01%	6985
2023 Q2	$48	Buy	12 +1	+9%	+$4	﹤0.01%	7064
2023 Q1	$41	Hold	11	–	–	﹤0.01%	7162
2022 Q4	$32	Buy	11 +8	+267%	+$27	﹤0.01%	7142
2022 Q3	$0	Hold	3	–	–	﹤0.01%	6678
2022 Q2	$0	Hold	3	–	–	﹤0.01%	6816
2022 Q1	$0	Hold	3	–	–	﹤0.01%	7075
2021 Q4	$0	Buy	3 +1	+50%	+$56	﹤0.01%	7230
2021 Q3	$0	Sell	2 -1	-33%	-$66	﹤0.01%	6977
2021 Q2	$0	Buy	3 +1	+50%	+$78	﹤0.01%	6912
2021 Q1	$0	Hold	2	–	–	﹤0.01%	6896
2020 Q4	$0	Buy	+2	New	+$99	﹤0.01%	6495
2020 Q3	–	Hold	0	–	–	–	6342

Other funds holding BNTC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Wells Fargo's BNTC Position: Q1 2026 in Review

Wells Fargo reduced its Benitec Biopharma (BNTC) stake by 57% in Q1 2026, selling an estimated $107K and leaving 7,045 shares worth $75K. The position accounts for ﹤0.01% of the portfolio, ranked #5262.

Wells Fargo first reported a position in BNTC in Q4 2020 and has held it in 18 quarters since. The position peaked at $219K in Q4 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

Wells Fargo held 7,045 shares of Benitec Biopharma worth $75K as of Q1 2026.
Wells Fargo sold 9,217 Benitec Biopharma shares in Q1 2026, an estimated $107K.
Benitec Biopharma made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5262 holding.
Wells Fargo first reported a position in Benitec Biopharma in Q4 2020 and has held it in 18 quarters since.
Wells Fargo's Benitec Biopharma position peaked at $219K in Q4 2025.
88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.